

RDH11,14,DHRS3,DRHS4 reduce atRAL to atROL

Duester, G., Jassal, B., Napoli, JL.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](https://creativecommons.org/licenses/by/4.0/). For more information see our [license](https://reactome.org/licenses/).

06/05/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 88


This document contains 1 reaction ([see Table of Contents](#))

RDH11,14,DHRS3,DRHS4 reduce atRAL to atROL [↗](#)

Stable identifier: R-HSA-5419165

Type: transition

Compartments: cytosol, endoplasmic reticulum membrane



Multiple reductases may contribute to the reduction of all-trans-retinal (atRAL) to all-trans-retinol (atROL), including RDH11 (aka PSDR1, RaIR1), RDH14, DHRS3 (aka retSDR1, RDH17) and DHRS4 (aka RRD, SCAD-SRL) (Haeseleer et al. 1998, Haeseleer et al. 2002, Kedishvili et al. 2002, Lin et al. 2001, Zhen et al. 2003, Belyaeva et al. 2008).

Literature references

- Chen, W., Zhang, M., Napoli, JL., Lei, Z. (2003). Reduction of all-trans-retinal in the mouse liver peroxisome fraction by the short-chain dehydrogenase/reductase RRD: induction by the PPAR alpha ligand clofibrate. *Biochemistry*, 42, 4190-6. [↗](#)
- Imanishi, Y., Driessen, CA., Nelson, PS., Palczewski, K., Haeseleer, F., Jang, GF. et al. (2002). Dual-substrate specificity short chain retinol dehydrogenases from the vertebrate retina. *J. Biol. Chem.*, 277, 45537-46. [↗](#)
- Lebioda, L., Huang, J., Saari, JC., Haeseleer, F., Palczewski, K. (1998). Molecular characterization of a novel short-chain dehydrogenase/reductase that reduces all-trans-retinal. *J. Biol. Chem.*, 273, 21790-9. [↗](#)
- Belyaeva, OV., Korkina, OV., Stetsenko, AV., Kedishvili, NY. (2008). Human retinol dehydrogenase 13 (RDH13) is a mitochondrial short-chain dehydrogenase/reductase with a retinaldehyde reductase activity. *FEBS J.*, 275, 138-47. [↗](#)
- Vessella, R., Wang, S., Ferguson, C., Bumgarner, R., Lin, B., Hood, L. et al. (2001). Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium. *Cancer Res.*, 61, 1611-8. [↗](#)

Editions

2014-04-16	Authored	Jassal, B.
2014-05-01	Edited	Jassal, B.
2014-07-28	Reviewed	Duester, G.
2014-09-01	Reviewed	Napoli, JL.